Screener
Castle Biosciences CSTL Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accrued compensation | 19,111 | 38,287 |
| Contingent consideration | 1,000 | 1,000 |
| Operating lease liabilities | 1,254 | 1,325 |
| Current portion of long-term debt | 1,667 | 417 |
| Other accrued and current liabilities | 10,691 | 8,937 |
| Total current liabilities | 48,761 | 68,677 |
| Long-term debt | 8,399 | 9,640 |
| Noncurrent portion of contingent consideration | 1,500 | 1,500 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's current debt?
- Castle Biosciences (CSTL) reported current debt of $1.67M in Q1 2026.
- How has Castle Biosciences's current debt changed year-over-year?
- Castle Biosciences's current debt increased by 50.0% year-over-year, from $1.11M to $1.67M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Castle Biosciences's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude